Clinical features according to TCR and genotypic subsets
. | Patients, N . | Sex ratio, F/M . | Median age, y (range) . | Median WBC, 109/L (range) . | Mediastinal involvement, %* . |
|---|---|---|---|---|---|
| All patients | 91 | 17/74 | 29 (16-55) | 68 (0.5-624) | 57 |
| TCR subsets† | |||||
| Immature | 31/91 | 6/25 | 29 (17-52) | 21.7 (0.5-281)‡ | 53 |
| Pre-αβ | 29/91 | 5/24 | 34 (16-50) | 70.5 (1.1-368) | 59 |
| TCR-αβ+ | 18/91 | 3/15 | 29 (16-55) | 120 (7.6-624)§ | 47 |
| TCR-αβ+ | 13/91 | 3/10 | 28 (21-39) | 100 (37-152) | 75 |
| Genotypic subsets∥ | |||||
| CALM-AF10 | 8/81 | 1/7 | 28.5 (23-43) | 23.4 (2.2-105)§ | 75 |
| SIL-TAL1 | 11/81 | 2/9 | 22 (16-45)‡ | 169 (15.9-624)‡ | 50 |
| HOX11 | 11/81 | 2/9 | 36 (17-47) | 70.5 (5.1-260) | 73 |
| HOX11L2 | 10/81 | 3/7 | 27 (17-52) | 21.9 (7.8-299) | 30¶ |
| TAL1 | 22/69 | 2/20 | 25.5 (16-50)¶ | 96 (1.1-620)¶ | 50 |
| LYL | 8/69 | 1/7 | 31.5 (21-52) | 33 (0.5-177) | 62.5 |
| LMO2 | 15/69 | 3/12 | 26 (16-52) | 31 (0.5-256) | 38 |
. | Patients, N . | Sex ratio, F/M . | Median age, y (range) . | Median WBC, 109/L (range) . | Mediastinal involvement, %* . |
|---|---|---|---|---|---|
| All patients | 91 | 17/74 | 29 (16-55) | 68 (0.5-624) | 57 |
| TCR subsets† | |||||
| Immature | 31/91 | 6/25 | 29 (17-52) | 21.7 (0.5-281)‡ | 53 |
| Pre-αβ | 29/91 | 5/24 | 34 (16-50) | 70.5 (1.1-368) | 59 |
| TCR-αβ+ | 18/91 | 3/15 | 29 (16-55) | 120 (7.6-624)§ | 47 |
| TCR-αβ+ | 13/91 | 3/10 | 28 (21-39) | 100 (37-152) | 75 |
| Genotypic subsets∥ | |||||
| CALM-AF10 | 8/81 | 1/7 | 28.5 (23-43) | 23.4 (2.2-105)§ | 75 |
| SIL-TAL1 | 11/81 | 2/9 | 22 (16-45)‡ | 169 (15.9-624)‡ | 50 |
| HOX11 | 11/81 | 2/9 | 36 (17-47) | 70.5 (5.1-260) | 73 |
| HOX11L2 | 10/81 | 3/7 | 27 (17-52) | 21.9 (7.8-299) | 30¶ |
| TAL1 | 22/69 | 2/20 | 25.5 (16-50)¶ | 96 (1.1-620)¶ | 50 |
| LYL | 8/69 | 1/7 | 31.5 (21-52) | 33 (0.5-177) | 62.5 |
| LMO2 | 15/69 | 3/12 | 26 (16-52) | 31 (0.5-256) | 38 |
WBC indicates white blood cell count.
Criteria for positivity are given in “Patients, materials, and methods.”
All the 91 patients were studied and patients from each subset were compared with those from the other 3 subsets.
P < .01.
P < .05.
HOX11, HOX11L2, SIL-TAL1, and CALM-AF10testing was performed in 81 of the 91 patients and patients from each subset were compared with all other patients tested. LYL, LMO2, and TAL1 testing was performed in 69 patients only and patients from each subset were compared with all other patients tested.
P < .10.